Xceleron, JCL Bioassay Partner on Screening Technologies | GenomeWeb

NEW YORK (GenomeWeb News) – Xceleron announced today that it will collaborate with JCL Bioassay in offering drug developers access to their respective technologies for drug screening and development applications.

Xceleron said that the partnership will offer clinical design expertise and appropriate analytical platforms for early clinical investigation. It added that between the firms they have developed more than 100 analytical methods for Phase 0 and Phase 1 investigations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.